Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
1All Rights Reserved Health Sciences Authority
Dr Liu Yan Ping Regulatory Consultant
Pharmaceuticals & Biologics Branch Health Products Regulation Group
Health Sciences Authority, Singapore
Electronic Nicotine Delivery DevicesChallenges and Opportunities
14th ICDRA 3 December 2010
2All Rights Reserved Health Sciences Authority
WHO Regulatory Consultation on the Safety of Electronic Nicotine Delivery Devices
6-7 May 2010Participants:
– Delegates of WHO Member States*– Experts– WHO Study Group on Tobacco Product
Regulation (TobReg)– the Convention Secretariat and WHO staff
*Australia, Brazil, Canada, European Commission, Saudi Arabia, Serbia, Singapore, South Africa, Switzerland, Thailand, Turkey, Ukraine and United States
3All Rights Reserved Health Sciences Authority
OVERVIEW• What are ENDS?
• WHO Study Group on Tobacco Product Regulation Report (January 2010)
• WHO Regulatory Consultation on the Safety of ENDS (May 2010)– Recommendations
• Summary
4All Rights Reserved Health Sciences Authority
WHAT ARE ENDS?Electronic Nicotine Delivery Devices (ENDS) :
– Battery powered devices– Designed to deliver nicotine to the lungs– Contain tobacco-derived substances, but not
tobacco– Variety of brand names and descriptors – e.g.,
“electronic cigarettes”, “e-cigs”
5All Rights Reserved Health Sciences Authority
Three main components:– Nicotine cartridge– Atomization chamber– Smart chip + lithium ion battery
5
BASIC DESIGN
6All Rights Reserved Health Sciences Authority
MODELS AND BRANDING
BASIC DESIGN
7All Rights Reserved Health Sciences Authority
MARKETING OF ENDS
• First marketed in 2004• Significant increase in global distribution and
sales• The increase coincides with the implementation
of Article 8 of the WHO Framework Convention on Tobacco Control (FCTC) that is leading to the introduction of smoke-free environments in many countries
8All Rights Reserved Health Sciences Authority
9All Rights Reserved Health Sciences Authority
WHO FCTC• Article 1(f) defines tobacco products
as:“those products entirely or partly
made of the leaf tobacco as raw material which are manufactured to be used for smoking, sucking, chewing or snuffing.”
• ENDS are not tobacco products under this definition.
• ENDS are technically not under the reach of this global treaty against the tobacco epidemic.
10All Rights Reserved Health Sciences Authority
WHO TobReg and ENDS
• The fifth meeting of the WHO TobReg addressed regulation of ENDS (Nov 2008)
• Recommendation on ENDS to the WHO126th Executive Board meeting (Jan 2010)
11All Rights Reserved Health Sciences Authority
Recommendations for Regulatory Policy1. ENDS products should be regulated as combination drugs
and medical devices and not as tobacco products;
2. If ENDS are regulated under tobacco control laws, ENDS should be subject to the same regulation as tobacco control;
3. Regulators should weigh the theoretical benefits of ENDS and the risks that the products will appeal to nonsmokers;
4. Regulatory authority to confirm the evidence before approving these products for sale and marketing;
5. Claims implying health benefits or less harm than cigarettes should be prohibited;
6. Claims that ENDS assist smoking cessation should be prohibited.
12All Rights Reserved Health Sciences Authority
WHO Regulatory Consultation on the Safety of ENDS
• Meeting was held in May 2010• The purpose:
– share national regulatory experiences;– raise awareness of potential safety concerns
related to ENDS;– consider current and future approaches to
regulation;– map out means of promoting and protecting
public health through research and the development of clear regulatory guidelines.
13All Rights Reserved Health Sciences Authority
Concerns identified:• Lack of understanding of the chemicals used in
ENDS and absence of any published studies demonstrating their efficacy and safety
• Lack of data to confer the claimed cigarette mimicking sensory characteristics when heated and delivered to the lung
• The precise nature and the quantity of constituents in the emissions are unknown
WHO Regulatory Consultation on the Safety of ENDS
14All Rights Reserved Health Sciences Authority
Recommendations (1)1. Nicotine is a highly toxic and addictive substance that
poses a serious risk to health. Nicotine and nicotine products for human use should be regulated.
2. ENDS products may be used to deliver other potentially toxic chemicals and drug ingredients. These products are often accompanied by inaccurate information. Regulators are concerned that the quality and safety of these products has not been established.
3. Regulators of medical and tobacco products should collaborate in assessing the regulatory framework within their own countries to determine the most effective means of regulating (or possibly banning) ENDS to protect public health.
15All Rights Reserved Health Sciences Authority
Recommendations (2)
4. Where health and/or therapeutic claims are being made or implied, quality, safety and efficacy data substantiating those claims should be presented to the regulator.
5. National regulators are encouraged to inform the public and other interested parties about concerns related to these products, including their safety and misleading marketing, and to share information among themselves about these products, including research findings and related policies.
6. National regulators encourage WHO to facilitate information exchange between tobacco control and medical products regulators.
16All Rights Reserved Health Sciences Authority
7. Decided to establish two informal working groups:– A Regulators' Information Document Working Group
to put together an informational document for regulators.
– A Consumer Information Document, addressing the consumer.
Recommendations (3)
17All Rights Reserved Health Sciences Authority
Consumer Information Document
Working group led by Health Canada: for consumers and public
- What are ENDS- Perceived benefits of ENDS are not supported - Risks of ENDS and nicotine- No regulatory agency has granted marketing
authorization for ENDS- Advised not to purchase or use these products
18All Rights Reserved Health Sciences Authority
• Significant increase in global distribution and sales of ENDS
• No data to support the quality, safety and efficacy of ENDS
• Regulatory gap exists for ENDS• Regulators should assess the regulatory
framework to determine the most effective means of regulating ENDS to protect public health.
Summary
19All Rights Reserved Health Sciences Authority
Thank youAcknowledgement:Tobacco Free InitiativeQuality Assurance and Safety: MedicinesWHO